Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -359.19% is 84% above its 2-year average of -2294.55%, near the high end of its 2-year range (-18134.62%–6089.32%).
74.26% above its 12-month average of -1395.52%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2024 (2024-12-31): 6089.32%.
EBITDA MARGIN
-359.19%
EBITDA MARGIN AVG TTM
-1395.52%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+74.26%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Amylyx Pharmaceuticals, Inc.
Market Cap
$3.09B
EBITDA Margin
-359.19%
TTM Avg
-1395.52%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.15B
EBITDA Margin
-1.82%
TTM Avg
-32.91%
3Y Avg
-2154.05%
5Y Avg
-2154.05%
Market Cap
$3.16B
EBITDA Margin
-54.45%
TTM Avg
-179.51%
3Y Avg
-231.98%
5Y Avg
-287.87%
Market Cap
$2.88B
EBITDA Margin
89.92%
TTM Avg
49.57%
3Y Avg
44.47%
5Y Avg
4968.54%
Market Cap
$2.87B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$3.44B
EBITDA Margin
10.88%
TTM Avg
18.32%
3Y Avg
-3.89%
5Y Avg
-19.05%
Market Cap
$2.69B
EBITDA Margin
11.88%
TTM Avg
11.88%
3Y Avg
7.44%
5Y Avg
-2.29%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | $3.09B | -359.19% | -1395.52% | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | -1.82% | -32.91% | -2154.05% | -2154.05% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | -54.45% | -179.51% | -231.98% | -287.87% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | N/A | N/A | N/A | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | 89.92% | 49.57% | 44.47% | 4968.54% |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 22.42% | 17.70% | -0.76% | -37.34% |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 3.20% | -0.69% | -3.43% | -1.09% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 10.88% | 18.32% | -3.89% | -19.05% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 11.88% | 11.88% | 7.44% | -2.29% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | 17.42% | 19.36% | 20.74% | 18.34% |
Gross Margin
0.0%
EBITDA Margin
-359.2%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2024-12-31 | 6089.32% |
| 2024-09-30 | -18134.62% |
| 2024-06-30 | 5203.03% |
| 2024-03-31 | -137.42% |
| 2023-12-31 | 2.06% |
| 2023-09-30 | 18.52% |
| 2023-06-30 | 20.85% |
| 2023-03-31 | -2.59% |
| 2022-12-31 | -202.93% |
| 2022-09-30 | -15801.74% |
